Although CSF-1R inhibition has been shown to inhibits GBM tumor growth in a preclinical study27, clinical trials using a CSF-1R inhibitor for cancer treatment failed due to its toxicity66–68, because CSF-1R is expressed by many types of immune cells including monocytes69,70. Here, CSF1R is linked to neoplasm.